AbbVie Inc. (ABBV)
  • CONTENT
AbbVie Inc. (ABBV)
Voyager up 16% premarket on AbbVie deal
Voyager Therapeutics (NASDAQ: VYGR ) is up 16% premarket on light volume in response to its collaboration and option agreement with AbbVie (NYSE: ABBV ) aimed and developing and commercializing vectorized alpha-synuclein-targeting antibodies for the treatment of Parkinson's dis…
AbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies
NORTH CHICAGO, Ill. and CAMBRIDGE, Mass. , Feb. 22, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurologi…
Gilead (GILD): why this stock is undervalued
Gilead stock looks slightly undervalued at this point because the market is undervaluing Gilead’s HIV and oncology portfolios. What is the potential for this stock?
AbbVie (ABBV): Will The Stock Recover?
ABBV diverted the Rova-T program today—and that led to its stock price fall by 13%. When will the stock bounce back?
AbbVie Inc. (ABBV)